Grupo de Investigación en Farmacoepidemiología y Farmacovigilancia, Universidad Tecnologica de Pereira-Audifarma S. A, Calle 105 No. 14-140, Pereira, Risaralda, 660003, Colombia.
Grupo Biomedicina, Facultad de Medicina, Fundación Universitaria Autónoma de las Américas, Pereira, Colombia.
Int J Clin Pharm. 2021 Aug;43(4):900-908. doi: 10.1007/s11096-020-01194-y. Epub 2020 Nov 12.
Background Erectile dysfunction is associated with old age, some morbidities and the use of certain medications. Objective To identify the treatments and drugs related to worsening sexual activity in patients with erectile dysfunction. Setting Patients diagnosed with erectile dysfunction during 2018. Methods This cross-sectional study of a population database identified all drug prescriptions of patients with erectile dysfunction during 2018. Main outcome measure The identification of other comorbidities and potentially inappropriate drugs that could worsen erectile dysfunction. Results A total of 2999 patients with erectile dysfunction (mean age 59.6 ± 12.1 years) were identified. A total of 88.2% received pharmacological treatment for erectile dysfunction, mainly tadalafil (70.5%). A total of 47.6% of all patients received at least one medication associated with worsening erectile dysfunction, especially hydrochlorothiazide (17.0%), metoprolol (7.9%) and sertraline (6.7%). Residing in Cali (OR 1.86; 95% CI 1.52-22.27) or Bucaramanga (OR 2.23; 95% CI 1.39-33.58), having 3 or more chronic comorbidities (OR 1.52; 95% CI 1.04-2.24) and presenting psychiatric (OR 5.5; 95% CI 3.70-8.17), cardiovascular (OR 3.48; 95% CI 2.79-4.33), genitourinary (OR 1.31; 95% CI 1.05-1.64) pathologies or chronic kidney failure (OR 1.84; 95% CI 1.18-2.21) elevated the probability of receiving these prescriptions. Conclusions The pharmacological treatment of erectile dysfunction was in accordance with the recommendations of clinical practice guidelines, but the high proportion of potentially inappropriate prescriptions makes it necessary to promote educational and pharmacovigilance strategies that improve the prescription habits of physicians involved in caring for this group of patients.
背景 勃起功能障碍与年龄、某些疾病和某些药物的使用有关。目的 确定与勃起功能障碍患者的性活动恶化相关的治疗方法和药物。设置 在 2018 年期间被诊断为勃起功能障碍的患者。方法 本研究对人群数据库进行了一项横断面研究，以确定 2018 年期间所有勃起功能障碍患者的药物处方。主要结局指标 识别可能导致勃起功能障碍恶化的其他合并症和潜在不适当药物。结果 共确定了 2999 名勃起功能障碍患者（平均年龄 59.6±12.1 岁）。88.2%的患者接受了治疗勃起功能障碍的药物治疗，主要是他达拉非（70.5%）。共有 47.6%的患者接受了至少一种可能导致勃起功能障碍恶化的药物治疗，特别是氢氯噻嗪（17.0%）、美托洛尔（7.9%）和舍曲林（6.7%）。居住在卡利（OR 1.86；95%CI 1.52-22.27）或布卡拉曼加（OR 2.23；95%CI 1.39-33.58）、患有 3 种或更多种慢性合并症（OR 1.52；95%CI 1.04-2.24）和出现精神科（OR 5.5；95%CI 3.70-8.17）、心血管（OR 3.48；95%CI 2.79-4.33）、泌尿生殖系统（OR 1.31；95%CI 1.05-1.64）疾病或慢性肾衰竭（OR 1.84；95%CI 1.18-2.21）的患者，更有可能接受这些处方。结论 勃起功能障碍的药物治疗符合临床实践指南的建议，但潜在不适当处方的比例很高，这使得有必要实施教育和药物警戒策略，以改善参与照顾这群患者的医生的处方习惯。
